REVOLUTION Medicines Announces First Patient Dosed with RMC-4630

REVOLUTION Medicines announced dosing of the first patient in a Phase 1, open-label, monotherapy dose-escalation and expansion study of RMC-4630, the company’s lead investigational drug candidate targeting the enzyme SHP2. REVOLUTION Medicines holds the IND for RMC-4630, and this trial is being conducted under the recently announced global partnership on SHP2 between REVOLUTION Medicines and Sanofi. Initiation of this clinical trial represents an important step in the company’s mission to translate frontier oncology targets on behalf of cancer patients.

“REVOLUTION Medicines is proud to advance RMC-4630 into clinical development on behalf of patients with advanced cancers who have limited treatment options,” said Stephen Kelsey, M.D., FRCP, FRCPath, president of R&D of REVOLUTION Medicines. “Our discovery of optimal inhibitors of SHP2 and elucidation of the critical role of SHP2 in the growth of certain cancers has, for the first time, suggested the potential to render these drivers of cancer clinically actionable. We are eager to advance this program by working with patients, experienced clinical investigators and our development partners at Sanofi.”

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of RMC-4630 in people with relapsed, refractory solid tumors including non-small cell lung cancer and other tumor types carrying certain mutations that cause hyperactivation of the RAS-MAP kinase cell growth signaling cascade. Despite notable recent therapeutic advances in the management of lung cancer and melanoma, there remain large unmet medical needs as no targeted therapies have been approved for treating patients with solid tumors carrying these specific mutations. The study will comprise two parallel components: (1) a dose escalation study for patients with solid tumors, and (2) an expansion study for patients with tumors harboring specific mutations.

Original research led by scientists at REVOLUTION Medicines, and conducted in collaboration with researchers at the University of California, San Francisco School of Medicine, discovered that cancers caused by these oncogenic signaling proteins rely on the normal biochemical actions of SHP2. These data were first disclosed in preliminary form in 2017 via BioRxiv, and have now been published in a full peer-reviewed paper in Nature Cell Biology. They demonstrated that cancers with such “semi-autonomous” mutations may be susceptible to treatment with an inhibitor of SHP2. The trial of RMC-4630 will explore precision oncology hypotheses based on these findings at several clinical centers, including the University of California, Irvine, Chao Family Comprehensive Cancer Center.

  • <<
  • >>

Comments